JAZZ News and Press, Jazz Pharmaceuticals plc From 09/20/23

2023-09-20 08:30:53 ET NetworkNewsWire Editorial Coverage New York, NY – September 20, 2023 – More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

2023-09-16 16:00:56 ET On Sept. 14, the Multidisciplinary Association for Psychedelic Studies ("MAPS") announced positive results on a second phase 3 trial for MDMA -- also known as ecstasy -- for post-traumatic stress disorder that were published in a scientific journal. The data in th...

Jazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences PR Newswire DUBLIN , Sept. 13, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming investor confere...

2023-09-12 07:40:45 ET More on Jazz Pharmaceuticals Seeking Alpha’s Quant Rating on Jazz Pharmaceuticals Jazz Pharmaceuticals: Depressed Valuation Opens Up Potential Jazz Pharmaceuticals: Xywav Debate Continued Drag On Equity Performance Jazz Pharma wi...

Jazz Pharmaceuticals Announces Key Update to Leadership Team PR Newswire Renée Galá promoted to President and Chief Operating Officer DUBLIN , Sept. 12, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Renée...

Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023 PR Newswire Six presentations demonstrated Jazz's commitment to providing solutions for people living with difficult-to-treat sleep disorders Review of multiple clinical trials...

2023-09-11 03:06:49 ET Summary Zymeworks is a biotech company focused on developing therapies for hard-to-treat cancers. Its lead product, zanidatamab, has shown promising results in clinical trials and has been partnered with larger pharmaceutical companies. The company also ...

2023-09-04 07:46:14 ET Summary Zymeworks, a biotech firm, specializes in biotherapeutics for cancers, with primary product zanidatamab targeting HER2 and collaborations with BeiGene and Jazz Pharmaceuticals. Financially robust with $431.4M cash, revenue surged due to a Jazz deal, ...

Jazz Pharmaceuticals to Participate in Citi's 18th Annual BioPharma Conference PR Newswire DUBLIN , Aug. 24, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Citi Annual BioPharma Conferenc...

2023-08-16 03:00:21 ET Summary Baupost Group's 13F portfolio value decreased from $5.85B to $5.61B this quarter. The portfolio is heavily concentrated, with Liberty Global, Liberty Media Sirius XM, ViaSat, Alphabet, and Veritiv accounting for approximately 58% of the holdings. ...